Triple
T1169412
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Spinraza |
E24879
|
entity |
| Predicate | modifiesGeneExpression |
P14972
|
FINISHED |
| Object |
SMN2
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
|
E135135
|
NE FINISHED |
How this triple was built (5 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: SMN2 | Statement: [Spinraza, modifiesGeneExpression, SMN2]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: SMN2 Context triple: [Spinraza, modifiesGeneExpression, SMN2]
-
A.
SOD1
SOD1 is a gene encoding the antioxidant enzyme superoxide dismutase 1, whose mutations are a major known cause of familial amyotrophic lateral sclerosis (ALS).
-
B.
C9orf72
C9orf72 is a human gene whose hexanucleotide repeat expansions are the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
-
C.
survival motor neuron protein
Survival motor neuron protein is an essential cellular protein required for the maintenance and function of motor neurons, whose deficiency leads to spinal muscular atrophy.
-
D.
spinal muscular atrophy
Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
-
E.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: SMN2 Triple: [Spinraza, modifiesGeneExpression, SMN2]
Generated description
SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: SMN2 Target entity description: SMN2 is a human gene that produces a backup form of survival motor neuron protein and is a key therapeutic target in spinal muscular atrophy.
-
A.
SOD1
SOD1 is a gene encoding the antioxidant enzyme superoxide dismutase 1, whose mutations are a major known cause of familial amyotrophic lateral sclerosis (ALS).
-
B.
C9orf72
C9orf72 is a human gene whose hexanucleotide repeat expansions are the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
-
C.
survival motor neuron protein
Survival motor neuron protein is an essential cellular protein required for the maintenance and function of motor neurons, whose deficiency leads to spinal muscular atrophy.
-
D.
spinal muscular atrophy
Spinal muscular atrophy is a genetic neuromuscular disorder characterized by progressive muscle weakness and atrophy due to degeneration of motor neurons in the spinal cord.
-
E.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
- F. None of above. chosen
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: modifiesGeneExpression Context triple: [Spinraza, modifiesGeneExpression, SMN2]
-
A.
leafModification
Indicates a relationship where an entity undergoes or causes a change in the structure, form, or characteristics of a leaf.
-
B.
geneticInfluence
Indicates that one entity affects or contributes to the genetic traits, characteristics, or heredity of another entity.
-
C.
regulatoryInteraction
chosen
Indicates a relationship where one entity modulates, controls, or influences the activity, expression, or function of another entity through regulatory mechanisms.
-
D.
isFrequentlyAdapted
Indicates that a work or source material is often transformed or re-created into new formats or versions, such as films, plays, or other media.
-
E.
mayBeModifiedBy
Indicates that an entity has the potential to be altered, changed, or updated by another entity or process.
- F. None of above.
Provenance (6 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a494082a7c819095004f423f294a64 |
completed | March 1, 2026, 7:31 p.m. |
| NER | Named-entity recognition | batch_69a4bce821b481908bc278a3fa7973f4 |
completed | March 1, 2026, 10:25 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ac6f17aa608190920b7df62b8dd903 |
completed | March 7, 2026, 6:31 p.m. |
| NEDg | Description generation | batch_69ac6fc5442c8190a5d824881f05d468 |
completed | March 7, 2026, 6:34 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ac7026dda48190a72f671dba9ac17b |
completed | March 7, 2026, 6:36 p.m. |
| PD | Predicate disambiguation | batch_69a4bb5656948190b0b1d5446ad06005 |
completed | March 1, 2026, 10:19 p.m. |
Created at: March 1, 2026, 7:45 p.m.